The L3MBTL2 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population that enables functional studies of L3MBTL2 in a colorectal adenocarcinoma context. This pool of HT29 cells carries CRISPR/Cas9-mediated disruptions at the L3MBTL2 locus, resulting in a loss-of-function model. As a polyclonal population, it offers a practical tool for investigating gene function without the need for clonal isolation.
The HT29 cell line, derived from a primary colon adenocarcinoma of a 44-year-old female, is a well-established model for colorectal cancer research. These epithelial cells harbor mutations in APC and TP53, which drive aberrant WNT and p53 signaling. HT29 cells are widely utilized to study tumor biology, epithelial barrier function, and therapeutic responses, making them an ideal host for examining epigenetic regulators such as L3MBTL2.
L3MBTL2 is a methyl-histone reader that recognizes H3K27me3 and H4K20me2 marks, acting within a non-canonical PRC1-like complex alongside RING1 and YY1 to mediate chromatin compaction and transcriptional repression. Its expression is regulated by E2F transcription factors and miR-218, connecting it to cell cycle control. L3MBTL2 targets include CDKN1A (p21) and HOX gene clusters, and its recruitment depends on PRC2-mediated H3K27me3 deposition by EZH2. Through these interactions, L3MBTL2 links histone modification readout to stable gene silencing and cellular homeostasis.
In the HT29 background, L3MBTL2 knockout disrupts Polycomb-directed chromatin compaction, potentially leading to derepression of tumor suppressors like p21 and altered expression of developmental regulators. Given the existing APC and TP53 mutations, this model helps elucidate the interplay between genetic lesions and epigenetic dysregulation in colorectal cancer. The polyclonal population permits the study of phenotypic diversity and dominant effects resulting from L3MBTL2 loss on proliferation, apoptosis, and differentiation.
Applications include RNA-seq and ChIP-qPCR for target gene discovery, functional assays for proliferation, apoptosis, and migration, and drug sensitivity testing with epigenetic inhibitors such as EZH2 or HDAC blockers. The cells can be analyzed by flow cytometry for cell cycle distribution and by western blotting for pathway verification. For further information, please contact Ascent Research.
